Log in to save to my catalogue

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY...

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10427426

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing (
n
 = 72, cohort 1), HER2-low (
n
 = 74, cohort 2) and HER2 non-expressing (
n
 = 40, c...

Alternative Titles

Full title

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10427426

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10427426

Other Identifiers

ISSN

1078-8956,1546-170X

E-ISSN

1546-170X,1744-7933

DOI

10.1038/s41591-023-02478-2

How to access this item